PPA
RVNC

Parametric Portfolio Associates’s Revance Therapeutics, Inc. RVNC Stock Holding History

Parametric Portfolio Associates’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$5.41M Sell
277,250
-90,482
-25% -$1.37M ﹤0.01% 1797
2021
Q4 		$6M Buy
367,732
+98,664
+37% +$1.64M ﹤0.01% 1732
2021
Q3 		$7.5M Buy
269,068
+667
+0.2% +$19K ﹤0.01% 1547
2021
Q2 		$7.96M Buy
268,401
+7,748
+3% +$223K ﹤0.01% 1549
2021
Q1 		$7.29M Buy
260,653
+959
+0.4% +$26.5K ﹤0.01% 1903
2020
Q4 		$7.36M Sell
259,694
-36,497
-12% -$945K ﹤0.01% 1813
2020
Q3 		$7.45M Buy
296,191
+42,801
+17% +$1.12M 0.01% 1593
2020
Q2 		$6.19M Sell
253,390
-16,189
-6% -$320K ﹤0.01% 1729
2020
Q1 		$3.99M Sell
269,579
-67,150
-20% -$1.39M ﹤0.01% 1903
2019
Q4 		$5.46M Buy
336,729
+81,921
+32% +$1.27M ﹤0.01% 2005
2019
Q3 		$3.31M Buy
254,808
+143,593
+129% +$1.76M ﹤0.01% 2321
2019
Q2 		$1.44M Buy
111,215
+53,810
+94% +$678K ﹤0.01% 2856
2019
Q1 		$905K Buy
57,405
+4,787
+9% +$83K ﹤0.01% 3080
2018
Q4 		$1.06M Buy
52,618
+5,784
+12% +$127K ﹤0.01% 2948
2018
Q3 		$1.16M Buy
46,834
+9,429
+25% +$256K ﹤0.01% 3010
2018
Q2 		$1.03M Sell
37,405
-35,444
-49% -$1.07M ﹤0.01% 3042
2018
Q1 		$2.24M Sell
72,849
-6
-0% -$193 ﹤0.01% 2539
2017
Q4 		$2.6M Buy
72,855
+37,808
+108% +$1.09M ﹤0.01% 2423
2017
Q3 		$966K Buy
35,047
+5,935
+20% +$144K ﹤0.01% 3069
2017
Q2 		$769K Buy
29,112
+1,711
+6% +$38.2K ﹤0.01% 3127
2017
Q1 		$570K Buy
27,401
+1,524
+6% +$31.3K ﹤0.01% 3137
2016
Q4 		$536K Buy
25,877
+5,040
+24% +$84.4K ﹤0.01% 3152
2016
Q3 		$338K Sell
20,837
-231
-1% -$3.35K ﹤0.01% 3364
2016
Q2 		$287K Sell
21,068
-1,856
-8% -$32.8K ﹤0.01% 3468
2016
Q1 		$400K Buy
+22,924
New +$467K ﹤0.01% 3447

Other funds holding RVNC

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parametric Portfolio Associates's RVNC Position: Q1 2022 in Review

Parametric Portfolio Associates reduced its Revance Therapeutics, Inc. (RVNC) stake by 25% in Q1 2022, selling an estimated $1.37M and leaving 277,250 shares worth $5.41M. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Parametric Portfolio Associates first reported a position in RVNC in Q1 2016 and has held it in 25 quarters since. The position peaked at $7.96M in Q2 2021. 157 funds tracked by Wall St. Rank hold RVNC as of Q1 2022.

  • Parametric Portfolio Associates held 277,250 shares of Revance Therapeutics, Inc. worth $5.41M as of Q1 2022.
  • Parametric Portfolio Associates sold 90,482 Revance Therapeutics, Inc. shares in Q1 2022, an estimated $1.37M.
  • Revance Therapeutics, Inc. made up ﹤0.01% of Parametric Portfolio Associates's portfolio in Q1 2022, its #1797 holding.
  • Parametric Portfolio Associates first reported a position in Revance Therapeutics, Inc. in Q1 2016 and has held it in 25 quarters since.
  • Parametric Portfolio Associates's Revance Therapeutics, Inc. position peaked at $7.96M in Q2 2021.
  • 157 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2022.

Based on Parametric Portfolio Associates's 13F filing for Q1 2022, filed 16 May 2022.